Breaking Dawn - Part 2 Sweeps the Razzies









02/23/2013 at 10:00 PM EST







Taylor Lautner and Mackenzie Foy, in Breaking Dawn – Part 2


Andrew Cooper, SMPSP/Summit


Who's misérable now?

The Twilight Saga: Breaking Dawn – Part 2, Adam Sandler and Rihanna are among the "winners" of the 33rd annual Golden Raspberry Awards – the Razzies – which are not so much handed out as they are thrown at those who are voted as perpetrating Hollywood's worst achievements of the year.

Breaking Dawn – Part 2, the fifth and final installment in Stephenie Meyer's vampire saga, was recognized in seven categories, including worst picture.

The flick's Kristen Stewart was also cited as worst actress; Taylor Lautner, worst supporting actor; Lautner and 12-year-old Mackenzie Foy, worst screen couple; the entire cast, including Robert Pattinson, worst screen ensemble, and Bill Condon, worst director.

In addition, the film, which since opening last November has taken in more than $828 million at the box office, was named worst sequel.

Sandler, who last year monopolized the Razzies – and set a record by winning in 10 categories with the "comedy" Jack & Jill – this year got only two awards: for worst actor of the year and worst screenplay, both for That's My Boy.

Unlike the Oscars, which keep voting tallies a secret and will be handed out Sunday night during a very glamorous event, founder and Head RAZZberry John Wilson announced Razzie recipients Saturday night in the utilitarian Continental Breakfast Room of the Holiday Inn Express Hollywood Walk of Fame hotel, near (and yet so far from) the Dolby Theatre, home of the Academy Awards.

Wilson revealed to the press that although Rihanna, as worst supporting actress in the movie Battleship, won her Razzie by a landslide, worst screenwriter Sandler only beat the authors of Breaking Dawn by a single vote.

It's close shaves like that that really make or break the Razzies.

Breaking Dawn – Part 2 Sweeps the Razzies| Oscars 2013, The Razzies 2013, Movies, Battleship, That's My Boy, News Franchises, Individual Class, Adam Sandler, Kristen Stewart, Rihanna, Robert Pattinson

Adam Sandler, in That's My Boy, and Rihanna, in Battleship

Columbia; Universal

The 85th annual Academy Awards will air live on ABC starting at 7 p.m. ET/4 p.m. PT on Sunday, Feb. 24, from the Dolby Theatre in Hollywood.
Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.


Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.


Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.


"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.


Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.


But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.


National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.


"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.


OPTIONS BULLS TARGET GAINS


The spending cuts, if they go ahead, could hit the defense industry particularly hard.


Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.


Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.


"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.


The stock ended up 0.6 percent at $88.12 on Friday.


If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.


General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.


EYES ON GDP DATA, APPLE


The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.


U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.


Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.


Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.


On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.


(Additional reporting by Doris Frankel; Editing by Kenneth Barry)



Read More..

Catholic Church Fills Growing Void in Africa





LAGOS, Nigeria — The young woman slept soundly on the cool marble floor before the altar, a break from the chaos at home. In the courtyard, neighborhood teenagers filled giant jerrycans with purified water from a stone fountain. In an aisle, a rail-thin young woman from a nearby slum said she had not eaten since yesterday but was expecting sustenance here.




Behind its high spiked iron gates in this frenetic megalopolis of anywhere between 11 million and 21 million, the church of Christ the King is protector, feeder and healer.


In the 6 a.m. darkness, this working-class church is already filled with parishioners in shirt-sleeves and T-shirts, a pool of hymn-singing light in a blacked-out neighborhood. Six Masses are celebrated here each Sunday for up to 10,000 people, and 102 people were baptized last Saturday. The parish priest, the Rev. Ikenna Ikechi, dreams of building a multistory community center to accommodate his growing flock. “Our only limitation is space,” he said.


The Roman Catholic Church’s explosive growth here and across Africa has led to serious talk of the possibility of an African cardinal succeeding Pope Benedict XVI, and clerics from Nigeria, Ghana and the Democratic Republic of Congo, which has the continent’s largest Catholic population, have been mentioned as top contenders.


With 16 percent of the world’s Catholics now living in Africa, the church’s future, many say, is here. The Catholic population in Africa grew nearly 21 percent between 2005 and 2010, far outstripping other parts of the world. While the number of priests in North America and Europe declined during the same period, in Africa they grew by 16 percent. The seminaries, clerical officials here say, are bursting with candidates, and African priests are being sent to take over churches in former colonial powers.


Untainted by the child sexual abuse scandals, the church here draws parishioners, many in their 20s and 30s, who flock eagerly to services, which can last hours, with no complaints.


“After work, a lot of young people come to Mass,” said Chinedu Okani, 29, an engineer in Lagos who was attending a service at the Church of the Assumption in the Falomo neighborhood. “It provides a serene environment.”


He acknowledges another attraction, too: that the church is a functioning institution in a country that lacks them.


“The welfare system is not working here,” Mr. Okani said. “We find a way to make up for it: the family, and the church.”


In Nigeria, at least 70 percent of the people live below the poverty line, and 80 percent of the country’s oil wealth goes to 1 percent of the population. The police do not respond to calls, and electricity is spotty.


Outside Christ the King, on the dirt streets of the Mushin neighborhood, there are armed robbers and no lights. It is little wonder that the priest must gently shoo away parishioners lingering to read or chat in the church’s arcaded meeting spaces under generator-powered lights.


“A lot of it is the challenge of living in Nigeria,” said Father Ikechi, who was educated at Fordham University in New York. “We can’t rely on the government for water, light, security. Whatever you want, you have to provide for yourself.”


For his parishioners, he said, “what they face is huge. So they tend to come to God as their last resort. You can’t go to the police. Who will you go to? You will go to God. Some of them, where they sleep is so bad, they just come to sleep here during the day.”


After a devastating bus accident recently the church paid parishioners’ hospital bills, the priest said. “Otherwise they would die,” he said.


In this way the church is fulfilling a role it played in its distant European past, providing for the people where the state cannot, but some question whether the African church’s growth and size can be sustained as the continent’s institutions develop.


“When people say Africa is the future, I say, ‘Oh, isn’t it the past?’ ” said the Rev. Thomas J. Reese, a senior fellow at the Woodstock Theological Center at Georgetown University. “I see it as a repeat of the past, what happened in Europe centuries ago. What’s going to happen in Africa when everybody gets a television set, when modernity comes?”


For now, that question is largely academic here.


“Almost every system has collapsed,” said Bishop Matthew Hassan Kukah of Sokoto, in northwestern Nigeria. “The entire architecture of governance has collapsed. The church remains the only moral force.


“The church offers the best schools, social services, medicine. The God talk in Africa is a mark of the failure of the economic, social and political system,” Bishop Kukah added, “We are being called left, right and center to mend the broken pieces of what are considered the failing states of Africa.”


In a continent rife with corruption, the church also provides a singular moral voice. Bishop Kukah, for example, has played a large role in good governance and human rights commissions, including the investigation into the 1990s military dictatorship.


In Congo, where the number of Catholics has more than tripled in the past 35 years, Archbishop Laurent Monsengwo Pasinya of Kinshasa has fiercely criticized the government, including the tainted election results that secured President Joseph Kabila’s re-election in 2011. The Catholic Church deployed an extensive network of independent observers during the December elections, and the bishops’ council later denounced the “culture of treachery, lies and terror.”


“It’s the church’s engagement on behalf of the Congolese people, the promotion of the whole man, you’ve got to bring forth bread and the Gospels,” said Bishop Bernard-Emmanuel Kasanda of Mbuji-Mayi in Congo. “We have to be with the people. Moral authority, yes. This is what pushes people towards us.”


In Nigeria, where over $5 billion was reported missing from a minerals ministry on Friday, the latest in a series of seemingly endless government scandals, the church offers an alternative to a life mired in corruption, poverty and hopelessness.


Laurence Emeka, 30, who sells telephone accessories at an open-air stall, rose at 5 a.m. last Sunday to attend Mass at Christ the King before going to work. The service gave him a kind of sanctuary. “Peace, satisfaction, confidence in God,” he said. “It helps me cope with the circumstances of daily life.”


Gaia Pianigiani contributed reporting from Rome.



Read More..

Einhorn scores legal victory vs. Apple in cash scuffle






NEW YORK (Reuters) – A U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with Apple Inc on Friday, blocking the iPhone maker from moving forward with a shareholder vote on a controversial proposal to limit the company’s ability to issue preferred stock.


U.S. District Judge Richard Sullivan in Manhattan granted a motion by Einhorn’s Greenlight Capital for a preliminary injunction stopping a vote on that proposal, scheduled for the company’s February 27 stockholders’ meeting.






The decision could hand Einhorn more leverage as he pursues his pitch for Apple to issue what he has called the “iPref”: preferred stock with a perpetual dividend that he contends would reward investors and help boost the company’s share price.


Greenlight sued Apple on February 7 as part of a broader pitch to unlock more of its $ 137 billion in cash. The hedge fund manager has lobbied Apple to issue preferred stock with a perpetual 4 percent dividend, and on Thursday made a direct appeal to shareholders on a teleconference.


The lawsuit itself challenged a measure called Proposal No. 2 that Apple put forward, which would eliminate its power to issue preferred shares without a shareholder vote.


At issue is Apple’s “bundling” of that measure with two other unrelated matters into a single proxy proposal.


Greenlight said it supported two of the proposed amendments, but not the one on preferred shares.


In his ruling, Sullivan said Greenlight and another investor who also sued Apple “are likely to succeed on the merits and face irreparable harm if the vote on Proposal No. 2 is permitted to proceed.”


“We are disappointed with the court’s ruling. Proposal No.2 is part of our efforts to further enhance corporate governance and serve our shareholders’ best interests,” Apple spokesman Steve Dowling said. “Unfortunately, due to today’s decision, shareholders will not be able to vote on Proposal #2 at our annual meeting next week.”


A spokesman for Greenlight called the ruling a “significant win for all Apple shareholders and for good corporate governance.”


But not all shareholders were happy. California pension fund CalPers, a major Apple investor and public supporter of Apple’s proposal, said implementation of “majority voting and shareholder approval for the issuance of new stock – preferred or otherwise – is worth waiting for.”


“We encourage Apple to reintroduce these measures as soon as is practical so that all investors can be heard,” Anne Simpson, CalPers’ Director of Global Governance, said in a statement.


BUNDLES


The ruling could be a warning for other companies when issuing proxy proposals, said James Cox, a professor at Duke University School of Law.


“It’s going to make managers reluctant to bundle things together, because you’re never going to know when you send them out if there’s an Einhorn out there,” he said.


The lawsuit was centered on a narrow issue of whether Apple violated U.S. Securities and Exchange Commission rules by “bundling” the preferred shares item with two other unrelated matters into one proxy proposal.


Greenlight’s lawyers contended the SEC rules were intended to protect shareholders from being forced to vote for a proxy proposal involving materially different issues that the investors might not entirely support.


Apple had argued Proposal No. 2, which only dealt with amendments to its charter, constitute a single matter and wasn’t bundled. Sullivan called the company’s arguments “unavailing.”


“Given the language and purpose of the rules, it is plain to the Court that Proposal No. 2 impermissibly bundles ‘separate matters’ for shareholder consideration,” Sullivan wrote.


Judge Sullivan also found that Greenlight would be irreparably harmed without the injunction, since it would be forced to vote against its own interests. Denying Greenlight‘s motion would prevent it and other investors for exercising their rights to a fair vote, Sullivan said.


Sullivan separately declined to block a vote from going forward on a separate proxy proposal, Proposal No. 4, which sought an advisory “say on pay” vote on Apple executives’ compensation.


The proposal had been challenged by investor Brian Gralnick of Pennsylvania, who contends Apple did not disclose enough details about how it made its compensation decisions.


Sullivan rejected that argument, saying Apple’s disclosures were “plainly sufficient under SEC rules.”


Arnold Gershon, a lawyer for Gralnick at Barrack, Rodos & Bacine, did not respond to a request for comment.


Apple shares closed up 1.1 percent at $ 450.81 on Friday.


The case is Greenlight Capital LP, et al., v. Apple Inc., U.S. District Court, Southern District of New York, 13-900.


(Reporting By Nate Raymond in New York; additional reporting by Poornima Gupta in San Francisco; Editing by Martha Graybow, Gary Hill, Leslie Adler and Carol Bishopric)


Tech News Headlines – Yahoo! News





Title Post: Einhorn scores legal victory vs. Apple in cash scuffle
Url Post: http://www.news.fluser.com/einhorn-scores-legal-victory-vs-apple-in-cash-scuffle/
Link To Post : Einhorn scores legal victory vs. Apple in cash scuffle
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Courtney Lopez: Gia Thinks Our Dog Is Having a Baby




Celebrity Baby Blog





02/22/2013 at 01:00 PM ET



Courtney Lopez: Gia Thinks Dog Having Baby
Denise Truscello/Wireimage


Mario Lopez is a man of his word.


Following a December wedding, the EXTRA host declared he and wife Courtney would get to work expanding their family immediately — and he wasn’t kidding.


In January, the couple discovered they were indeed expecting.


“Mario and I are so excited to add to our family! I found out a month ago and surprised Mario with the good news at breakfast,” Courtney tells PEOPLE.


But the proud parents aren’t the only ones gearing up for a new addition. Big sister Gia Francesca, 2, already has babies on the brain.


“Gia kind of understands that there is a baby in my belly,” Courtney notes. “She also told me our dog Julio has a baby in his belly — so who knows!”

Despite a bumpy start — “I had a rough couple of weeks when I first found out,” she shares — the mom-to-be is feeling better and already sporting quite the blossoming belly. “I am showing so much faster this time around,” she says.


And with warmer weather on the way, Courtney will be swathing her bump in floor-length frocks — but plans on foregoing a few fashion ensembles from her past.


“I love being pregnant in the summer! I live in maxi dresses,” she says. “Looking back at my first pregnancy, there are certain things that I wore and I have no idea why. I looked horrible and I won’t do that again!”


Originally from Pittsburgh, the expectant mama is thrilled to have settled down with her growing family on the West Coast. Her only wish? That her children will one day enjoy a winter wonderland.


“I don’t miss the East Coast at all — especially the humidity,” she explains. “The one thing I do want my children to experience from an early age is snow. There is nothing like being a kid playing in the snow.”


– Anya Leon


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

U.S., Japan agree on approach to Trans-Pacific Partnership talks


WASHINGTON (Reuters) - The United States and Japan on Friday agreed on language aimed at giving Japanese Prime Minister Shinzo Abe political cover to bring the world's third-largest economy into negotiations on a U.S.-led free trade agreement in the Asia Pacific region.


In a carefully worded statement following Abe's meeting with President Barack Obama, the two countries reaffirmed that "all goods would subject to negotiation" if Japan joins the talks with the United States and 10 other countries.


At the same time, the statement leaves open a possible outcome to the Trans-Pacific Partnership, or TPP, talks where the Japan could still protect its rice sector and the United States could keep duties on Japanese autos.


"Recognizing that both countries have bilateral trade sensitivities, such as certain agricultural products for Japan and certain manufactured products for the United States, the two governments confirm that, as the final outcome will be determined during the negotiations, it is not required to make a prior commitment to unilaterally eliminate all tariffs upon joining the TPP negotiations," the statement said.


Jeffrey Schott, a senior fellow at the Peterson Institute for International Economics, called the joint statement "a big step forward" in the process of determining whether Japan will join TPP talks, which members hope to finish this year.


"The United States and Japan agreed that the deal has to be comprehensive, but you don't commit to the final terms before you even get into the negotiations," Schott said.


But Representative Sander Levin, the top Democrat on the powerful House of Representatives Ways and Means Committee, called the statement "worrisome" and warned any agreement that includes Japan would not pass Congress unless it truly pries open that country's farm and automotive markets.


Abe, who is on his first trip to Washington since taking office in December, has vowed to revive Japan's economy with an expansive monetary policy, big spending and structural reform.


Joining the TPP talks could help with the third task by exposing Japanese companies and farmers to more competition.


But Japanese rice and other farmers who have long enjoyed high tariff protections are opposed to Tokyo entering the talks, and Abe curried their favor during his campaign last year by promising not to unilaterally agree to eliminate tariffs on certain sensitive products.


The current TPP members - United States, Canada, Mexico, Australia, New Zealand, Chile, Peru, Singapore, Malaysia, Vietnam and Brunei - have pledged to negotiate an agreement that eliminates tariffs in as many areas as possible.


To accomplish that goal they have agreed not to exclude any sectors or products from the negotiations.


That stance also worries Ford Motor Co and the United Auto Workers, which have pressured the Obama administration not to allow Japan into the talks until Tokyo makes reforms to open its market to more auto imports.


Although Japan already has no auto tariffs, Ford and the UAW argue that the country relies on regulatory and other non-tariff barriers to keep out auto imports.


The U.S.-Japan joint statement said the two governments would continue their discussions on the possibility of Japan joining the TPP talks.


"While progress has been made in these consultations, more work remains to be done," in areas such as autos and insurance, the joint statement said.


A final decision to allow Japan into the negotiations would have to be made by all the current TPP members.


Additionally, the White House would have to give Congress 90 days notice before starting talks with Japan.


(Additional reporting by Mark Felsenthal; Editing by David Brunnstrom and Eric Walsh)



Read More..

BBC Portrayed as Top-Heavy, Bickering and Dysfunctional





LONDON — A senior press officer for the British Broadcasting Corporation darkly volunteers to “drip poison” to discredit a BBC reporter he suspects of having leaked embarrassing information. The woman in charge of the corporation’s news divisions accuses Newsnight, a public-affairs program she oversees, of being out of touch and “sneery” toward rival BBC shows.




And, as investigators seek to uncover why the corporation canceled a Newsnight broadcast alleging that a once-beloved BBC personality who had recently died had in fact been a serial pedophile who preyed on vulnerable girls, everyone involved is scrambling to deflect blame onto someone else.


These and other unflattering details about the inner workings of Britain’s public broadcaster emerged Friday when the BBC released some 3,000 pages of internal documents — e-mails, memos and transcripts of interviews — from an external investigation into why the program, about the BBC presenter Jimmy Savile, had been canceled.


In all, the documents painted a picture of a highly dysfunctional, top-heavy organization divided into discrete, rival factions, and weighed down by mistrust, poor communication, buck-passing and internecine squabbling.


There were no startling revelations; all those came out in the so-called Pollard report into the Savile affair, which was published in December and which concluded that there were deep structural problems in the BBC. But the supporting documents released Friday shed light on just what Nick Pollard, who prepared the report, meant by his scathing critique, said John Whittingdale, chairman of the House of Commons culture and media committee.


“It demonstrates the extent of unhappiness within the BBC structure, the frustration at the bureaucratic nature of the management, and the generally poor state of morale,” Mr. Whittingdale said in a television interview.


Referring to the fact that material in some of the newly released documents was blacked out, apparently because of concerns that it might give rise to lawsuits, Mr. Whittingdale added: “The fact that so much of the evidence can’t be published, because we are told the lawyers have advised it could be defamatory, in a sense tells its own story.”


Large portions of the testimony of Jeremy Paxman, a blunt-talking Newsnight host who is known for his testy and combative interview style, for instance, are blacked out in places where it appears he is about to make personal remarks about other people.


And in an annoyingly tantalizing instance, Peter Horrocks, director of global news, declares: “It is no secret that ...” What follows has been redacted, however, so that it is in fact a secret.


Lord McAlpine, a former Tory cabinet minister who, in another debacle at Newsnight, was unjustly accused of being a pedophile in a report that was broadcast, said that the BBC should not have left out any material. “The BBC is not the Secret Service, for Christ’s sake,” he told The Daily Telegraph.


But the BBC defended the redactions. Tim Davie, the acting director general, said that “97 percent plus of all the thousands of pages are out there.”


In an interview with an off-camera interlocutor that was broadcast on the BBC Web site, Mr. Davie continued: “We are not redacting or taking out material that is embarrassing or uncomfortable to the BBC. We have simply taken out stuff that external lawyers saw as a clear risk.”


He did not make himself available for interviews with other news organizations on Friday — indeed, no one from the BBC did. That strategy was roundly ridiculed by the broadcaster’s rivals.


On Twitter, Ben de Pear, editor of Channel 4 News, said that over his career he had successfully coaxed interviews out of Robert Mugabe of Zimbabwe and Mahmoud Ahmadinejad of Iran. “We are still trying for Tim Davie,” he said.


Much of the material focused on who said what to whom, and when, during Newsnight’s investigations into the allegations against Mr. Savile — and during the subsequent decision to cancel the broadcast. But there were also general interviews with many key figures in the corporation about what was wrong and how to fix it.


The testimony of Lord Patten, chairman of the BBC Trust, was particularly sharp, as he described the chaotic flow of information, the preponderance of high-ranking officials (the BBC had “more senior leaders than China,” he said) and the general mistrust within the corporation. “Is a lesson I should take from this that I can’t believe it when I’m told things by the next director general, that I have to query everything he says or the director of news says to me or whatever?” he asked rhetorically.


No, he said in response. “With the next director general I won’t — or his senior colleagues — I won’t begin every conversation on the assumption that he or she or they may not be telling me the whole truth,” he said. “I will want to be more convinced that there is a structure in place which ensures that the truth is being told.”


Lark Turner contributed reporting from London, and Matthew Purdy from New York.



Read More..

Goldman: PlayStation 4 could send Sony into a ‘downward spiral’







Count Goldman Sachs analyst Takashi Watanabe as being pessimistic on the PlayStation 4′s chances for success. Per Business Insider, Watanabe has penned a new research note that casts doubt not only on Sony’s (SNE) new console specifically, but on the gaming console business as a whole. Specifically, Watanabe thinks that smartphones and tablets are poised to erode consoles’ installed base because more people can get their gaming fix through cheap games such as Angry Birds and Cut the Rope rather than spending $ 60 to buy the latest version of Call of Duty. This lower installation base leads to negative reinforcement where developers are less likely to invest in developing top-notch games for the platform, which further erodes consumers’ willingness to shell out cash for the console.


[More from BGR: The insane pricing of the new HTC One]






“We see little reason for developers to produce top titles for platforms with a low installed base,” he writes. “In turn there is a danger the installed base will not grow because the content lineup is weak.”


[More from BGR: Google unveils $ 1,300 touch-enabled Chromebook Pixel [video]]


Just this week, mobile app data firm App Annie released a new report in conjunction with research firm IDC showing that mobile games for the first time ever generated more revenue than console games in the fourth quarter of 2012, so Watanabe certainly has some legitimate reasons to be concerned about the future upside of dedicated gaming consoles. Combine this with the fact that Nintendo (NTDOY) Wii U sales have absolutely tanked in the past few weeks, and it’s easy to see why there’s a lot of anxiety around the console industry at the moment.


This article was originally published on BGR.com


Gaming News Headlines – Yahoo! News





Title Post: Goldman: PlayStation 4 could send Sony into a ‘downward spiral’
Url Post: http://www.news.fluser.com/goldman-playstation-4-could-send-sony-into-a-downward-spiral/
Link To Post : Goldman: PlayStation 4 could send Sony into a ‘downward spiral’
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..